184906-29-4

Usage

Uses

Used in Pharmaceutical Research:
5-Methoxy-3,3-diMethylisoindolin-1-one is used as a building block in pharmaceutical research for its ability to modulate biological activities. Its unique structure allows for the development of new compounds with potential therapeutic applications.
Used in Organic Synthesis:
In the field of organic synthesis, 5-Methoxy-3,3-diMethylisoindolin-1-one serves as a key intermediate for the synthesis of various organic compounds. Its reactivity and functional groups make it a valuable component in the preparation of complex molecules.
Used in Drug Discovery:
5-Methoxy-3,3-diMethylisoindolin-1-one is utilized in drug discovery as a potential lead compound. Its ability to modulate biological activities makes it a promising candidate for the development of new drugs targeting specific diseases or conditions.
Used in the Development of New Materials:
5-Methoxy-3,3-diMethylisoindolin-1-one has potential applications in the development of new materials with specific chemical properties. Its unique structure and reactivity can be harnessed to create materials with tailored properties for various applications.
Further research on the properties and uses of 5-Methoxy-3,3-diMethylisoindolin-1-one is necessary to fully understand its potential impact in various fields, including medicinal chemistry, drug discovery, and material science.

Upstream product

• 17653-93-9 2-(3'-Methoxyphenyl)-2-methylpropionitrile 
• 17653-94-0 α-methyl-α-(3-methoxyphenyl)proprionic acid 
• 109138-26-3 1-(1-Isocyanato-1-methylethyl)-3-methoxybenzene 

Downstream Products

• 184906-31-8 5-Hydroxy-3,3-dimethyl-2,3-dihydroisoindol-1-one 
• 184906-32-9 3,3-Dimethyl-5-(1-phenyl-1H-tetrazol-5-yloxy)-2,3dihydroisoindol-1-one 
• 19194-52-6 3,3-dimethylisoindolin-1-one 

Relevant academic research and scientific papers

SUBSTITUTED BICYCLIC COMPOUNDS

Disclosed are compounds of Formulas (I), (II), (III), (IV), and (V) and/or a salt thereof, wherein R1 is OH or OP(O)(OH)2, and X1, X2, X3, R2, R2a, Ra, Rb, and Rc are defined herein. Also disclosed are methods of using such compounds as selective agonists for G protein coupled receptor S1P1, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.

NEW COMPOUNDS

The present invention encompasses compounds of general formula (1) wherein A, B, X, R1 to R3 are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, and t

Design, synthesis, and in vitro evaluation of cyclic nitrones as free radical traps for the treatment of stroke

Analogs of the cyclic nitrone free radical trap 1 (3,3-dimethyl-3,4- dihydroisoquinoline N-oxide, a cyclic analog of phenyl-tert-butylnitrone (PBN)) were prepared in which (1) the fused phenyl ring was replaced with a naphthalene ring, an electron rich heterocycle, or a dimethylphenol, (2) the nitrone-containing ring comprised five, six, or seven atoms, and (3) the gem- dimethyl group was replaced with spirocyclic groups. The most active antioxidant, which bears a dimethylphenol fused to a 7-membered ring nitrone (compound 6h), inhibited lipid peroxidation in vitro with an IC50 of 22 μM, a 75-fold improvement over that of 1. The previously observed correlation between lipophilicity and activity vs lipid peroxidation in vitro has been further substantiated and refined by this study. Moreover, certain classes of compounds (namely, dimethylphenols 6g, h and furan 6j) have now been found which are considerably more active in vitro than expected on the basis of their log k'(w) values.